Mirvie

SOUTH SAN FRANCISCO, CA · CIK 0002079310 · Medtech · Private

RNA-based blood test that detects circulating RNA signatures to predict preterm birth and pregnancy complications

mirvie.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$24M
1 Form D · Aug 2025
14 months since last filing
Contracts
—
No federal contracts on record
Patents
35
4 granted · 31 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$23,702,346
Form D · SEC

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1094Nielsen BioSciences, Inc.—$12M
1095Motus GI Holdings, Inc.—$26M
1096Zerigo Health, Inc.—$65M
1097Mirvie—$24M
109820/20 GeneSystems, Inc.—$4.1M
1099Radwave Technologies Inc.—$4.0M
1100ReddyPort, Inc.—$3.1M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 8 related persons
  • Min CuiDirector
  • Lisa IversonDirector
  • Maneesh JainDirector · Executive Officer · Promoter
  • Samir KaulDirector
  • Naomi KelmanDirector
  • Stanley LapidusDirector
  • Ursheet ParikhDirector
  • Stephen QuakeDirector

Patents

USPTO · 4 granted of 35

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.